COPD and Cardiovascular Disease

被引:130
作者
Andre, S. [1 ]
Conde, B. [2 ]
Fragoso, E. [3 ]
Boleo-Tome, J. P. [4 ]
Areias, V. [5 ,6 ]
Cardoso, J. [7 ,8 ]
机构
[1] Ctr Hosp Lisboa Ocidental, EPE CHLO, Hosp Egas Moniz, Pulmonol Dept, Lisbon, Portugal
[2] Ctr Hosp Tras Os Montes & Alto Douro, Pulmonol Dept, Vila Real, Portugal
[3] Ctr Hosp Lisboa Norte, EPE CHLN, Hosp Santa Maria, Pulmonol Dept, Lisbon, Portugal
[4] Hosp Prof Doutor Fernando Fonseca, EPE, Pulmonol Dept, Amadora, Portugal
[5] Ctr Hosp Algarve, EPE, Hosp Faro, Pulmonol Dept, Faro, Portugal
[6] Algarve Univ, Dept Biomed Sci & Med, Faro, Portugal
[7] Ctr Hosp Lisboa Cent, EPE CHLC, Hosp Santa Marta, Pulmonol Dept, P-11691024 Lisbon, Portugal
[8] Nova Univ, Nova Med Sch, Lisbon, Portugal
关键词
Chronic obstructive pulmonary disease; Cardiovascular Disease; Comorbidity; Diagnostic Techniques and Procedures; OBSTRUCTIVE PULMONARY-DISEASE; CAUSE-SPECIFIC MORTALITY; FIXED-DOSE COMBINATION; AIR-FLOW OBSTRUCTION; LONG-TERM MORTALITY; HEART-FAILURE; LUNG-FUNCTION; BETA-BLOCKERS; HAEMOPHILUS-INFLUENZAE; CARDIAC DYSFUNCTION;
D O I
10.1016/j.pulmoe.2018.09.006
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
COPD is one of the major public health problems in people aged 40 years or above. It is currently the 4th leading cause of death in the world and projected to be the 3rd leading cause of death by 2020. COPD and cardiac comorbidities are frequently associated. They share common risk factors, pathophysiological processes, signs and symptoms, and act synergistically as negative prognostic factors. Cardiac disease includes a broad spectrum of entities with distinct pathophysiology, treatment and prognosis. From an epidemiological point of view, patients with COPD are particularly vulnerable to cardiac disease. Indeed, mortality due to cardiac disease in patients with moderate COPD is higher than mortality related to respiratory failure. Guidelines reinforce that the control of comorbidities in COPD has a clear benefit over the potential risk associated with the majority of the drugs utilized. On the other hand, the true survival benefits of aggressive treatment of cardiac disease and COPD in patients with both conditions have still not been clarified. Given their relevance in terms of prevalence and prognosis, we will focus in this paper on the management of COPD patients with ischemic coronary disease, heart failure and dysrhythmia. (C) 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U.
引用
收藏
页码:168 / 176
页数:9
相关论文
共 101 条
[1]   Burden of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease [J].
Agarwal, Shikhar ;
Rokadia, Haala ;
Senn, Todd ;
Menon, Venu .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2014, 47 (02) :105-114
[2]   Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study [J].
Agarwal, Sunil K. ;
Heiss, Gerardo ;
Barr, R. Graham ;
Chang, Patricia P. ;
Loehr, Laura R. ;
Chambless, Lloyd E. ;
Shahar, Eyal ;
Kitzman, Dalane W. ;
Rosamond, Wayne D. .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (04) :414-422
[3]   Hypothesis: Does COPD have an autoimmune component? [J].
Agusti, A ;
MacNee, W ;
Donaldson, M ;
Cosio, M .
THORAX, 2003, 58 (10) :832-834
[4]   Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype [J].
Agusti, Alvar ;
Edwards, Lisa D. ;
Rennard, Stephen I. ;
MacNee, William ;
Tal-Singer, Ruth ;
Miller, Bruce E. ;
Vestbo, Jorgen ;
Lomas, David A. ;
Calverley, Peter M. A. ;
Wouters, Emiel ;
Crim, Courtney ;
Yates, Julie C. ;
Silverman, Edwin K. ;
Coxson, Harvey O. ;
Bakke, Per ;
Mayer, Ruth J. ;
Celli, Bartolome .
PLOS ONE, 2012, 7 (05)
[5]  
[Anonymous], 2017, GLOB STRAT ASTHM MAN
[6]  
[Anonymous], 2018, Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease
[7]  
[Anonymous], LANCET RESP MED
[8]  
[Anonymous], 2013, GLOBAL STRATEGY DIAG
[9]  
[Anonymous], COPD RES PRACTICE
[10]  
[Anonymous], EUR RESP J